Tin tức & Cập nhật

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Cardiac rehabilitation produces functional capacity gains and quality of life improvements in patients with coronary heart disease (CHD), and a history of COVID-19 does not blunt this effect, according to a study.

Patients with asthma and chronic obstructive pulmonary disease (COPD) appear to have an elevated risk of pertussis infection, according to the results of a systematic review and meta-analysis.

Universal decolonization using topical antiseptics is shown to reduce hospitalizations due to methicillin-resistant Staphylococcus aureus (MRSA) infection among elderly home residents in Hong Kong.

Among patients with inflammatory arthritis receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs, those with overweight or obesity face an increased risk of COVID-19 infection, according to a study from Singapore.

An antimicrobial stewardship intervention to reduce the use of piperacillin–tazobactam in children with acute appendicitis has been shown to result in improved clinical outcomes.

The V114-032 trial, presented at ESPID 2026, shows that administering the 15-valent pneumococcal conjugate vaccine (PCV15) reduces the incidence of first vaccine-type acute otitis media (VT-AOM) among healthy children.

Topical application of chlorhexidine 1% proves effective at reducing bacterial load in both mothers and neonates, according to the results of a randomized controlled trial.

Real-life use of letermovir in paediatric recipients of haematopoietic stem cell transplant (HSCT) is generally safe and prevents the development of cytomegalovirus (CMV) disease, as shown in a study presented at ESPID 2026.